Skip to main content
← All comparisons

Best AlphaSense Alternatives for Biotech Teams in 2026

Maven Bio provides live intelligence that carries relevant biopharma developments into source-linked revisions to selected working files1. For example, Maven Bio keeps research assessments current1, Citeline Pharmaprojects+ organizes drug-development landscapes2, and BioMCP retrieves public biomedical evidence3.

This guide examines alternatives to AlphaSense for biotech teams in 2026, with AlphaSense included as the reference product and its clinical-data offering described from its public documentation4. It covers pipeline monitoring, scientific and clinical research, connected company information, and the work required to keep an assessment current between decisions153.

Best AlphaSense Alternatives for Biotech Teams in 2026

Jump to a platform

How we assessed these platforms

This comparison asks which parts of a biotech assessment each AlphaSense alternative can support, from identifying competing programs to maintaining the final research file. We reviewed the providers' own product descriptions and technical documentation, preserving the boundaries of each named offering. Maven Bio publishes this guide, and its own entry is held to the same evidence standard, with every claim linked to a public page.

CriterionWhat we checked
Biotech research inputsAsset records, scientific evidence, company documents, and transaction information
Follow-up researchWays to revisit a landscape or investigate a development after the first assessment
Evidence in the answerCitations to primary documents or links back to the provider's underlying records
Deliverable maintenanceWhether research can revise a working file and preserve sources, history, and rollback
Assistant integrationDocumented routes for using the provider's evidence within an existing AI environment

The guide does not give an overall score. Teams weigh these criteria differently, so each entry below names the work the platform suits best, its published coverage, its price on record, and its limitations, and the quick picks above match platforms to common use cases8.

Research tasks compared for alternatives to AlphaSense

Maven Bio documents source-linked project-file edits with revision history and rollback. AlphaSense documents scheduled research and artifact updates19.

PlatformDrug and trial researchCompany or deal researchDevelopment-change researchFile delivery and maintained revisionsDocumented MCP connectionBuilt-in broker research
Maven Bio15108YesYesYesSource-linked edits, history, and rollbackYesNo
AlphaSense491112YesYesYesScheduled artifact updatesYesYes
Citeline Pharmaprojects+2YesYesSaved-search alertsNot describedNot describedNot described
AdisInsight613YesYesPhase and trial-status changesXML retrieval and data feedsYesNot described
Cortellis Competitive Intelligence714YesYesCurrent and historical statusWord and Excel exportsYesBroker reports inform drug content
BioMCP315YesNot describedNot describedJSON records and CLI outputYesNot described

Not described means the provider's public pages do not document it.

Prices on record

Quote only means no price is published.

ProductPrice on record
Maven BioQuote only16
AlphaSenseQuote only12
Citeline Pharmaprojects+Quote only2
AdisInsightQuote only6
Cortellis Competitive IntelligenceQuote only14
BioMCPNo software license fee under MIT17

Maven Bio

Best for

Biotech assessments that need to stay current after the initial research pass.

Maven Bio brings live intelligence into selected project files, carrying relevant clinical, regulatory, and company evidence into sourced revisions. Teams can inspect an edit, review the file's history, or roll it back before downloading the maintained assessment1.

The research starts from connected biopharma records and primary documents, including drugs, trials, companies, deals, and financings. MCP supplies evidence to compatible assistants, while API access, webhooks, and connectors support research in the team's existing environment518.

A biotech team can use an existing report, spreadsheet, or presentation as the starting format for a recurring assignment, with its own source preferences and assessment questions included in the instructions19. Maven Bio proposes research steps for the team to refine, then supports scheduled or on-demand execution against new assets and markets19. The workflow description includes internal context and custom data connections, and carries unresolved research questions forward into later reviews19.

The integration page also describes reusable research methods for asset assessments, comparisons, and event investigations in Claude, as well as structured-data queries for internal systems18. Structured research tables apply the same question across a candidate set filtered by indication, mechanism, or stage, with supporting quotes, evidence ratings, and research steps available within each answer20. Follow-up questions can then pass to the research agent for deeper investigation of an individual candidate20.

The research agent can return a focused answer, propose an approach for review, or carry out an investigation that produces finished deliverables, with attachments and changes to the instructions supported during the work21. Its public description includes source passages, claim checking, and comparison of study populations, endpoints, and evidence gaps21. Maven Bio can also monitor beyond an existing company list through indication, target, mechanism, or modality scope, allowing a biotech landscape to include newly relevant competitors22.

Coverage

Maven Bio's October 2026 FAQ lists 100,000+ drug products and 30,000+ companies in all therapeutic areas. Its evidence spans 11 source classes, including registries, regulatory agencies, scientific literature, congress abstracts, and company filings22.

Price on record

Quote only16. Maven Bio scopes its annual team license and shared AI allowance around the required data rights, people, research volume, assistant access, and application integrations16.

Pros

Selected research files receive cited updates as relevant evidence changes1; Word, Excel, and PowerPoint outputs carry the maintained work into subsequent reviews1.

Cons

Maven Bio's MCP access cannot write to external files10.

AlphaSense

Best for

Combining market documents and premium content with clinical research and generated deliverables.

AlphaSense brings broker research, expert calls, filings, and news together with structured clinical and drug information. Its beta clinical-data offering connects drug, indication, company, target, and mechanism profiles, with saved views, charts, and exports for supported tables. The sources include US, European, and Chinese regulatory and trial information4.

The beta SuperAnalyst product creates reports, presentations, spreadsheets, models, dashboards, watchlists, and memos. Scheduled automations can create or update artifacts with source citations, and a beta MCP connector returns cited answers inside supported assistants911.

The pricing page separates its Market Intelligence offering from Enterprise Intelligence, which adds integration of internal research and company documents12. Its listed premium sources include broker and independent research from more than 1,000 firms, alongside an expert transcript library, while its enterprise offering names agent API access and the SuperAnalyst MCP connection12. These are documented content and delivery options within AlphaSense's own packages, so the relevant subscription scope is part of evaluating an alternative for an existing research team12.

Within the clinical-data beta, entity profiles link studies with their associated drugs, companies, indications, targets, and mechanisms, and supported tables can be screened before export4. That structured route complements the document search and generated deliverables already described in AlphaSense's public research documentation49.

The beta documentation distinguishes files uploaded to an individual task from content added to a shared library, with a 50 MB per-file upload limit9. Saved table views preserve the chosen filters and columns for that table, while supported CSV exports contain the complete matching set rather than only the visible rows4. SuperAnalyst also documents daily, weekly, monthly, and quarterly scheduling, with up to 10 automations active simultaneously9.

Its US clinical-data collection includes patent and exclusivity dates, biosimilar and interchangeability relationships, orphan designations, and available generic-challenge activity, while the China collection includes trial identifiers, sponsors, phases, status, and approval information4.

Coverage

AlphaSense's platform page describes more than 500 million premium documents23.

Price on record

Quote only12. AlphaSense describes annual enterprise subscriptions or per-seat licensing, with a package tailored to the customer12.

Pros

Market content and structured life-sciences data can be researched together4; saved instructions and scheduled assignments support recurring deliverable work9.

Cons

Some clinical-data citation links remain under refinement during beta4; reactive market-event triggers for Skills are still described as forthcoming9.

Citeline Pharmaprojects+

Best for

Replacing a document-led pipeline search with a structured view of competing development programs.

Pharmaprojects+ organizes the biotech competitive landscape around assets and their development characteristics. Searches can combine mechanism, target, stage, modality, and geography, and the database retains programs that failed or were withdrawn2.

Company Compare examines active pipelines side by side, while drug similarity analysis identifies chemical, biological, and mechanistic comparators. Ella translates plain-language questions into searches and returns answers traceable to Pharmaprojects+ records, supporting an asset assessment that needs a defined competitor set2.

For an assessment centered on competitive development, the published analytical views examine phase progression, discontinuation patterns, and launch timing, with dashboards that organize the landscape by modality, mechanism, geography, and market potential2. These functions let the researcher define the asset set through development attributes before moving into the company's commercial documents or other research materials2.

The product offers direct questions to Citeline's subject specialists through Ask the Analyst, and Ella can build and validate the underlying search strategy2. Pharmaprojects+ connects with Trialtrove+ and Sitetrove for questions extending from the pipeline into clinical activity and research sites, while the annual historical views show how therapeutic focus has changed2.

Coverage

The published inventory exceeds 100,000 drug profiles, supported by more than 58,000 sources. Citeline also identifies over 3,700 mechanisms and 1,100 targets among the dimensions available for pipeline searches2. Citeline also describes dedicated rare-disease records covering more than 750 diseases, including orphan designations and sponsor information2.

Price on record

Quote only2. Pharmaprojects+ packages are discussed with Citeline according to the organization's intended research and access requirements2.

Pros

Asset filters support a biotech landscape organized around the program's development characteristics2; current research can be compared with historical pipeline views extending back to 19952.

Cons

The historical comparison is restricted to annual snapshots rather than intermediate pipeline states2.

AdisInsight

Best for

Investigating a biotech program's clinical and safety history alongside its development record.

AdisInsight supplies curated profiles that connect drug development with clinical trials, safety information, transactions, and patents. Its editorial narratives cover milestones, trial results, adverse events, and pharmacology, giving an asset review a scientific record beyond company reporting613.

Through MCP, an assistant can retrieve a drug profile, examine the related trial record, or search for changes over a selected period. Safety-report retrieval includes report text and passages relevant to the question, while chart and timeline operations organize the records for further analysis13.

An assistant can request a trial's editorial text on purpose, eligibility, interventions, results, and endpoints, or retrieve related tables covering study centers, investigators, identifiers, and history13. For a biotech assessment, that separates the drug's development narrative from the protocol-level evidence attached to an individual study13. Drug-resource retrieval also exposes organizations and brand names, while the development timeline can retain country, route, formulation, and patient-segment detail rather than collapsing every program into its highest phase13.

AdisInsight's website describes indication dashboards, charts built from search results, and direct questions to its subject specialists6. Its MCP knowledge-base operation explains record definitions, field meanings, dataset connections, and search behavior, which provides a documented way to inspect how an answer was assembled13.

Coverage

AdisInsight publishes an approximate total of 347,000 reports in its safety collection. That figure describes safety reports, not the number of drugs or trials in the wider service13.

Price on record

Quote only6. AdisInsight provides a specialist-contact route for commercial inquiries without listing a subscription price6.

Pros

A development assessment can draw on both the drug narrative and related safety material13; assistant queries can focus on progression, discontinuation, or other changes within a defined period13.

Cons

The MCP chart operation accepts no more than two grouping fields13.

Cortellis Competitive Intelligence

Best for

Adding drug-level development and commercial evidence to a biotech company assessment.

Cortellis offers a structured route from a company pipeline to the drugs, indications, territories, and deals behind it. The CCI assistant connection includes consensus sales forecasts and links its responses back to Cortellis content7.

Its programmatic drug service combines regulatory, patent, clinical, and transaction information across the development lifecycle. An assessment can retrieve those records as JSON or XML, or export supported results and reports in formats including Excel and Word14.

Clarivate's drug content is updated daily, with manually curated records and an editorial review process that includes fact validation14. Alongside development status, the collection describes structures, mechanisms, discovery and development organizations, reported sales, and forecasts for the companies marketing a drug14. More than 20 filters support a focused search, and the source list includes registry records, conference findings, company websites, patents, releases, and broker research reports14.

The assistant service distinguishes a compact structured overview from detailed responses tailored to a question, and allows retrieval of a selected drug section7. It also provides deal search, CSV drug-search results, and validated analytical operations, with rich visual displays dependent on the host's support for that interface7.

Coverage

The published Cortellis drug collection spans more than 2,300 diseases and contains over 80,000 drugs and biologics, including programs whose development is inactive14.

Price on record

Quote only14. The Cortellis Drugs API is licensed commercially, with pricing and access inquiries directed to Clarivate14.

Pros

Drug records connect pipeline research with commercial and transaction context14; Claude and Microsoft Copilot Studio are documented hosts for the CCI MCP service7.

Cons

The connector's supported clients exclude Microsoft 365 Copilot Chat7.

BioMCP

Best for

Retrieving public biomedical evidence through an assistant or code.

BioMCP provides a command-line interface and MCP server for scientific search and detailed retrieval across publications, genes, variants, drugs, diseases, and trials. Its trial sources include ClinicalTrials.gov and the National Cancer Institute's Clinical Trials Search service315.

Entity links support follow-up research, while batch retrieval and source metadata keep provenance attached to returned records. Article searches can select an upstream provider or combine sources, with different enrichment behavior for those modes15.

The project exposes selectable detail sections rather than requiring every query to return the entire record, and its JSON responses include source metadata and suggested follow-up commands15. Cross-entity operations connect a drug with trials or adverse events, a disease with drugs or articles, and a publication with linked entities, citations, or references15. That structure supports a scientific investigation connecting biological evidence and clinical records without treating those records as a premium company-document library15.

BioMCP documents a local MCP server, a Docker distribution, and a remote HTTP deployment option, as well as optional upstream credentials for particular sources and rate limits15. Its repository also describes gene-set enrichment and local analysis of downloaded study data, extending its scope beyond search results alone15.

Coverage

The maintained BioMCP repository identifies 72 directly queried biomedical sources, plus 10 additional sources represented within another provider's response15.

Price on record

BioMCP is available under the MIT license, which grants permission to use, modify, and distribute the software free of charge17.

Pros

Scientific evidence is available through both MCP and a command-line interface3; source metadata helps retain the origin of information used in an assessment15.

Cons

Pinning an article search to an explicit source disables cross-provider row enrichment15.

How to choose an AlphaSense alternative for biotech research

Start with the decision behind the biotech assessment, then identify which evidence has to remain available if the team changes its research platform24. A licensing review centered on target, modality, and development history can use the structured filters in Pharmaprojects+, while a clinical assessment can require the trial narratives and safety material described by AdisInsight213. If the existing assignment depends on broker reports, expert transcripts, or internal company documents, preserve those requirements explicitly because AlphaSense lists them within its market and enterprise research offerings12.

Next, check where the work ends up after the research, including the time between a new finding and an updated tracker, briefing, or board presentation1. Maven Bio describes maintaining selected Word, Excel, and PowerPoint files with source-linked edits, history, and rollback; AlphaSense documents scheduled artifact creation and updates, with the beta restrictions stated in its help material19. Compare those behaviors with the actual document used in the decision, and separately inspect the exported records, generated files, or assistant responses available from the other products under consideration141315.

Use your own programs to test the scope, following familiar clinical findings, development changes, and company announcements back to the public documents or underlying records returned by the platform542. Keep the study, indication, and geographic context attached to each finding, and check the particular interface in which it must be used, since Cortellis names supported assistants and BioMCP distinguishes combined-source retrieval from explicitly selected article sources715. Price comparisons should preserve the content and delivery rights in each offer, including AlphaSense's package distinctions, Maven Bio's integration scope, and the separate upstream-source requirements documented by BioMCP121615.

Frequently asked questions

What are alternatives to AlphaSense for biotech teams?

Maven Bio connects live intelligence to maintained assessments, while specialist alternatives address structured development landscapes and public biomedical retrieval123. Pharmaprojects+ provides preclinical-to-launch development research, so an alternative can be selected around the particular part of the biotech assessment it must support2.

Does AlphaSense now include clinical-trial and drug data?

Yes, its beta Clinical Trial & Drug Data offering links clinical and regulatory records with drugs, companies, indications, targets, and mechanisms4. It draws on US, European, and Chinese sources and supports filtering, charts, and exports, while some citation types remain under refinement4.

Can AlphaSense automate recurring research?

Yes, SuperAnalyst documents scheduled assignments that can create a new artifact or update an existing one with sources9. Its guide separately describes reactive market-event triggers as forthcoming, preserving a distinction between scheduled and event-triggered work9.

Which alternative supports pipeline monitoring and maintained files?

Maven Bio monitors relevant developments and applies cited revisions to selected project files1. Those files retain revision history and rollback and can be downloaded as Word, Excel, or PowerPoint deliverables1.

Which alternatives can provide research inside an AI assistant?

Maven Bio and Cortellis CCI document assistant connections for linked biopharma and commercial evidence57. AdisInsight and BioMCP provide MCP research interfaces, and AlphaSense documents a beta MCP connector for its research service13311.

Which alternative can monitor clinical trial readouts and show the underlying sources?

Maven Bio explicitly describes readout monitoring alongside retrieval of trial records and supporting publications or company releases5. Keep a posted registry result, a company announcement, and an expected readout date identified by their source type, since the evidence available for each comes through different records54.

Is a specialist database a complete replacement for market-document research?

It supplies a different research input, with Maven Bio combining connected records and maintained files, Pharmaprojects+ organizing development programs, and AdisInsight connecting development and safety evidence1526. BioMCP retrieves public biomedical records, whereas AlphaSense describes premium market documents alongside its structured clinical offering34.